June 2025 NasdaqGS: ZVRA 1 A Rare Approach to Therapeutics Cautionary Note Regarding Forward-Looking Statements Presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or our future financial performance. We generally identify forward-looking statements by terminology such as "may," "will," "would," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," " ...

Zevra Stockholders Re-Elect Wendy L. Dixon, Ph.D. and Tamara A. Favorito to the Company’s Board of Directors Board and Management Reaffirm Commitment to Driving Continued Growth and Progress Against Strategic Plan CELEBRATION, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (“Zevra,” or the “Company”), a commercial-stage company focused on providing therapies to people living with rare disease, announced that based on the final vote count certified by the independent Inspect ...

ISS, Glass Lewis, and Egan-Jones Unanimously Conclude Mangless Has Not Made a Compelling Case for Change Board and Management Urge Stockholders to Follow Proxy Advisors' Recommendation and Vote "FOR" Wendy L. Dixon, Ph.D. and Tamara A. Favorito on the WHITE Proxy Card and "WITHHOLD" for Mangless Nominees CELEBRATION, Fla., May 21, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) ("Zevra," or the "Company"), a commercial-stage company focused on providing therapies to people living with rar ...

Zevra Therapeutics (ZVRA) FY 2025 Conference May 20, 2025 12:30 PM ET Speaker0 Alright. Good afternoon, everyone. My name is Brandon Folks. I'm one of the biopharma analysts here at H. C. Wainwright. And joining me for a fireside chat from Zebra Therapeutics is CEO, Neil McFarlane. Neil, thank you very much. Speaker1 Yeah. Thank you for having us. Speaker0 So maybe just to start, do you wanna just spend a few minutes giving people a quick overview of Zebra and the products that you currently have? Speaker1 ...

Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.40 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 71.43%. A quarter ago, it was expected that this specialty pharmaceutical company would post a loss of $0.39 per share when it actually produced a loss of $0.67, delivering a surprise of -71.79%.Over the last four quart ...

Zevra Therapeutics (ZVRA) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Company Participants Nichol Ochsner - Vice President of Investor Relations & Corporate CommunicationsNeil McFarlane - President & CEOJoshua Schafer - CCOR. LaDuane Clifton - CFO, Secretary & TreasurerSumant Kulkarni - Managing DirectorJason Butler - Managing Director & Biotechnology Equity ResearchEddie Hickman - Vice President Conference Call Participants Lachlan Hanbury-Brown - Biotech Equity Research Analyst Operator Good afternoon ...

Zevra Therapeutics (ZVRA) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Speaker0 Good afternoon and thank you for joining Zebra's First Quarter twenty twenty five Financial Results and Corporate Update Conference Call. Today's call is being recorded and will be available via the Investor Relations section of the company's website later today. The host for today's call is Nicole Ochsner, SEBRA's Vice President. Please go ahead. Speaker1 Thank you, and welcome to those who are joining us. Today, we will prov ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File Number: 001-36913 Zevra Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-5894398 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. ...

资产出售业务 - 2025年4月1日公司完成向买方出售罕见儿科疾病优先审评凭证（PRV）[4] - 依据2月26日的资产购买协议，资产出售完成时公司从买方获得1.5亿美元的毛收入[5] 财务数据现金及投资情况 - 2025年4月7日公司发布新闻稿，截至2025年3月31日，公司现金、现金等价物和投资约为6870万美元[6][8] - 上述现金、现金等价物和投资信息基于2025年3月31日季度的初步未经审计信息和管理层估计[9]

Q1 2025 net revenue of $20.4 million, driven by product net revenue of $17.2 million Completed sale of PRV for gross proceeds of $150 million, positioning balance sheet to drive the Company’s commercial launches and development programs Company to host conference call and webcast today, May 13, 2025, at 4:30 p.m. ET CELEBRATION, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living ...